Vivor, the industry-leading patient financial assistance platform, announced their publication in ASCO’s JCO Oncology Practice, co-authored by Vivor adviser and Duke Chief Quality and Innovation Officer, Dr. Syed Yousuf Zafar. The study explores the financial experiences of 200 cancer patients. It compares patients who used a financial navigation tool powered by the Vivor platform versus a control group who received a list of financial assistance websites. The study revealed meaningful insights on the intersection of financial toxicity and cancer care.
To read more about the study and financial toxicity’s impact on medication adherence, click here for an interview with Dr. Zafar.
Kiio, the easy-to-use digital musculoskeletal solution that reduces and prevents lower-back pain through guided exercise, announced its expanded platform to include knee, neck, and hip pain programs. Kiio’s new programs for knee, neck and hip use the same evidence-based approach to deliver simple, easy, and effective MSK therapy directly to a member’s smartphone or tablet,
without the need for equipment or trackers.
Kiio has a proven track record of delivering value to its members, health plan, and employer clients. More than 60% of members have less pain within 1 week of using Kiio. Kiio has completed four longitudinal claims-data studies with clients, which demonstrated between 72% lower medical spend and up to 87% lower opioid use for those who used Kiio.
CEO Lydia Zeller highlighted Kiio’s immediate availability. “With Kiio, a person in pain can answer screening questions at 9 pm on a Friday, download Kiio, do their first personalized exercise therapy routine in 7 minutes, repeat the next 2 days, and be on their way to feeling better by the end of their weekend. That’s impactful.”
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
To read more, click here.
Seven Bridges last week announced a partnership with ZS that will combine ZS’s expertise in biomedical research services and data science with Seven Bridges technology platform enabling multi-omics analytics, spanning the translational to clinical continuum. The combination provides biopharmaceutical and biotechnology companies with a one-stop solution for innovation and scalability for multi-omics analysis. Together, ZS and Seven Bridges help clients create breakthrough science, accelerate drug discovery and increase the probability of success for new drug candidates.
“Working side by side with our clients to help streamline R&D data and increase speed to market to improve patients’ lives is at the core of what we do within ZS’s research and development efforts,” said Aaron Mitchell, principal and leader of ZS’s research and development excellence practice. “Our partnership with Seven Bridges provides our clients, and ultimately patients, a faster path to new treatments and diagnostics.”
To read more, click here.
As part of Blue Therapeutics‘ strategic expansion and ongoing fundraising activities we want to share insights into the exciting world of receptor interactions and demonstrate why they have to be considered drug targets in their own right. We also want to share how they ultimately create benefits for patients across a variety of indications with high unmet need.
Part 1: “The fundamentals of receptor interactions and their connection to side effects” by Ajay Yekkirala, CSO and Co-Founder of Blue Therapeutics. To read more, click here.
Follow us at www.bluetherapeutics.com
- LinkedIn: Blue Therapeutics
- Twitter: @bluetherapeutic
- Please contact us at: [email protected]
Picture: akindo, Getty Images
